Seres Therapeutics (MCRB) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

SER-109 for C. difficile Infection - SER-109 Phase 3 ECOSPOR III study showed a sustained clinical response rate of 88.9% compared to 58.7% in the placebo arm at 8 weeks[12] - SER-109 demonstrated a 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo at 8 weeks[13] - Approximately 453,000 cases of primary C. difficile infection occur within the U S each year, leading to an estimated $5 billion in healthcare burden[20] - There are approximately 170,000 episodes of recurrent C. difficile infection per year in the U S[20] SER-287 for Ulcerative Colitis - SER-287 Phase 1b study showed a statistically significant clinical remission improvement in the daily treatment arm, with 40% remission compared to 0% in the placebo arm[39, 41] - SER-287 daily arm GI AEs were 13.3% vs 45.5% in the placebo arm[43] - The ECO-RESET Phase 2b study of SER-287 in ulcerative colitis is nearly 90% enrolled, with topline results anticipated in H2 2021[51] Pipeline and Financial Status - Seres Therapeutics had $320 million in cash, cash equivalents, and short and long-term investments as of September 30, 2020[58] - The company is advancing multiple earlier-stage programs, including SER-301, SER-401, and SER-155, targeting ulcerative colitis, metastatic melanoma, and antibiotic-resistant bacterial infections, respectively[6, 53]